Breast Cancer Research Centre - WA | Nedlands, Australia

Research site

Site insights

Top conditions

Top treatments


Data sourced from

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 6 total trials

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

A first-in-human (FIH) study using SBT6050 and SBT6050 in combination with PD-1 inhibitors in HER2 expressing or amplified advanced malignancies

Active, not recruiting
HER2 Positive Solid Tumors
Drug: SBT6050
Drug: Cemiplimab

Patients with HER2-positive primary breast cancer (BC) who do not achieve complete response after appropriate neoadjuvant therapy are at higher risk...

Active, not recruiting
HER2-Positive Primary Breast Cancer
Residual Invasive Breast Cancer
Drug: DS-8201a
Drug: T-DM1

This is a prospective, two arm, international, multicenter, randomized, open-label Phase III study evaluating the addition of 2 years of palbociclib...

Active, not recruiting
Breast Cancer
Drug: Standard Adjuvant Endocrine Therapy
Drug: Palbociclib
Locations recently updated

The goal of this clinical study is to see if sacituzumab govitecan-hziy (SG) can improve life spans of people with HR+/HER2- metastatic breast cancer...

Locally Advanced or Unresectable Metastatic Breast Cancer
Stage IV Breast Cancer
Drug: Paclitaxel
Drug: Capecitabine

Trial sponsors

Amgen logo
Bristol-Myers Squibb (BMS) logo
Daiichi Sankyo logo
Gilead Sciences logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems